Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

  • Opazo-Ríos, Lucas
  • Tejera-Muñoz, Antonio
  • Soto Catalan, Manuel
  • Marchant, Vanessa
  • Mas Fontao, Sebastián
  • Lavoz, Carolina
  • Moreno, Juan Antonio
  • Fierro Fernandez, Marta
  • Ramos, Ricardo
  • Suarez-Alvarez, Beatriz
  • López-Larrea, Carlos
  • Ruiz-Ortega, Marta
  • Egido, Jesús
  • Rodrigues-Díez, Raúl R.
Diabetic nephropathy (DN) is the main leading cause of chronic kidney disease worldwide. Although remarkable therapeutic advances have been made during the last few years, there still exists a high residual risk of disease progression to end-stage renal failure. To further understand the pathogenesis of tissue injury in this disease, by means of the Next-Generation Sequencing, we have studied the microRNA (miRNA) differential expression pattern in kidneys of Black and Tan Brachyury (BTBR) ob/ob (leptin deficiency mutation) mouse. This experimental model of type 2 diabetes and obesity recapitulates the key histopathological features described in advanced human DN and therefore can provide potential useful translational information. The miRNA-seq analysis, performed in the renal cortex of 22-week-old BTBR ob/ob mice, pointed out a set of 99 miRNAs significantly increased compared to non-diabetic, non-obese control mice of the same age, whereas no miRNAs were significantly decreased. Among them, miR-802, miR-34a, miR-132, miR-101a, and mir-379 were the most upregulated ones in diabetic kidneys. The in silico prediction of potential targets for the 99 miRNAs highlighted inflammatory and immune processes, as the most relevant pathways, emphasizing the importance of inflammation in the pathogenesis of kidney damage associated to diabetes. Other identified top canonical pathways were adipogenesis (related with ectopic fatty accumulation), necroptosis (an inflammatory and regulated form of cell death), and epithelial-to-mesenchymal transition, the latter supporting the importance of tubular cell phenotype changes in the pathogenesis of DN. These findings could facilitate a better understanding of this complex disease and potentially open new avenues for the design of novel therapeutic approaches to DN., This work was supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/ 00119, PI17/01495, PI17/00130, PI20/00140, PI19/00184, PI20/00639, PI20/00487, PI20/00375, DTS20/00083, and DTS19/00093), Red de Investigación Renal REDINREN: RD16/0009 to MR-O (RD16/0009/0003) and to CL-L (RD16/0009/0020), Sociedad Española de Nefrología, “NOVELREN-CM: Enfermedad renal crónica: nuevas Estrategias para la prevención, Diagnóstico y tratamiento” (B2017/BMD-3751 to MR-O), “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN 2019-103294 to MR-O), Innovation programme under the Marie SkłodowskaCurie grant of the European Union’s Horizon 2020 (IMProve-PD ID: 812699 to MR-O), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017- 22369), Consejería de Salud y Familias-FEDER, Junta de Andalucía (PIGE-0052-2020 to JM), and Gobierno de Chile (S-2020-05 VIDCA-UACh to CL). RICORS program to RICORS2040 (KIDNEY DISEASE) RD21/0005/0002 to MRO; RD21/0005/0017 to CL-L.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

  • Cruzado, J.M.
  • Lauzurica, R.
  • Pascual, J.
  • Marcen, R.
  • Moreso, F.
  • Gutierrez-Dalmau, A.
  • Andrés, A.
  • Hernández, D.
  • Torres, A.
  • Beneyto, M.I.
  • Melilli, E.
  • Manonelles, A.
  • Arias, M.
  • Praga, M.
Introduction: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. Methods: This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium <10 mg/dl were randomized to paricalcitol (PAR) or calcifediol (CAL). The intention-to-treat population (PAR: n = 46; CAL: n = 47) was used for the analysis. The primary endpoint was the percentage of patients with serum iPTH >110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. Results: The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH <70 pg/ml in the PAR group than in the CAL group (63.4% vs. 37.2%; P = 0.03). No differences were observed in bone turnover biomarkers and bone mineral density. The estimated glomerular filtration rate was significantly higher in the CAL group than in the PAR group without differences in albuminuria. In protocol biopsies, interstitial fibrosis and tubular atrophy tended to be higher in the PAR group than in the CAL group (48% vs. 23.8%; P = 0.09). Both medications were well tolerated. Conclusion: Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation hyperparathyroidism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

  • Hernández, Domingo
  • Vázquez, Teresa
  • Alonso-Titos, Juana
  • León, Myriam
  • Caballero, Abelardo
  • Cobo, María Angeles
  • Sola, Eugenia|||0000-0002-9462-3342
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Ruiz-Esteban, Pedro
  • Cruzado, Josep María
  • Sellarés, Joana
  • Moreso, Francesc|||0000-0002-7267-3963
  • Manonelles, Anna|||0000-0003-2456-388X
  • Torio, Alberto
  • Cabello, Mercedes
  • Delgado-Burgos, Juan
  • Casas, Cristina
  • Gutiérrez, Elena
  • Jironda, Cristina
  • Kanter, Julia
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with.